Supporting Biotechs on the Journey to Market

Pre-Revenue Pre-Commercial & First
Product Launch Planning
Commercialisation Commercial & Supply Chain
Capability Development
Scaling Growth by Organic &
Non-Organic Strategies
Deloitte's Point of view A roadmap to initial public offerings Intelligent drug discovery. Powered by AI Deloitte's Point of view Measuring the return from pharmaceutical innovation Evolving the product launch paradigm in pharma Deloitte's Point of view Impact of political, tax and regulatory change on European life sciences supply chains Healthcare and Life Sciences Tax Predictions 2020 Deloitte's Point of view How to 'ACE' geographical expansion in Europe Innovative routes to market. Rethinking the life sciences distribution model Deloitte's Point of view The future awakens. Life Sciences and Health Care Predictions 2022 Under the spotlight. Data integrity in life sciences Deloitte's Point of view Human Capital Trends. Leading the social enterprise: Reinvent with a human focus Intelligent biopharma. Forging the links across the value chain Deloitte's Point of view Life sciences and health care M&A Impact of EU regulatory change on the global life sciences industry Deloitte's Point of view Healthcare and Life Sciences Tax Predictions 2020 Cost management practices and trends in the Life Sciences industry

The necessity of small to medium-sized life science companies in the response to the COVID-19 crisis has put the biotech industry in a well-deserved spotlight. Tasked with the development of novel diagnostics, vaccines and roll out of the world’s fastest ever clinical trials, the pandemic has created a paradigm shift for the biotech market. Investment has flowed inwardly to support this innovative landscape, with the UK biotech market alone reporting 60% growth in investment from previous years. Strong European foundations for biotechs further support this trend and provide opportunities for companies to expand geographically to capture wider patient audiences.

However, small to medium-sized life science companies still face significant challenges on their journeys to market. Successfully navigating the Biotech life cycle includes securing IP, managing R&D, raising funds (including IPO), launching product/portfolio and expanding operations geographically. Next-generation Biotechs (including cell and gene therapies) face further challenges from the added layer of complexity that surrounds how companies must address novel patient, product and payment journeys

What is Biotech-in-a-box™?

Deloitte’s network of Life-science Catalyst and Tech hubs exist to support the life-science ecosystem. At its centre, Biotech-in-a-box™️ provides a ‘one-stop shop’ to support the growth of small to mid-cap life sciences companies along their journey to market by leveraging Deloitte’s whole portfolio of capabilities and offerings. Our global footprint of over 9,000 practitioners in over 90 countries includes work with leading companies across the life sciences industry spanning across a diverse range of cross-functional capabilities (including Strategy, Research, Commercialisation, Tax, Finance, Legal, Supply Chain, Regulatory, Technology and Human Resource). We have expertise in delivery (the design, build and run of research/commercial operations), partnership (assessing partnership options, finding the right partner, and delivering the right risk/reward relationship), launch of products or services (supported >100 launch-related efforts in the last 12 months), and are skilled in end-to-end next generation capabilities to support the unique needs of small and mid-cap companies.

Across a biotech’s journey to market, Biotech-in-a-box continues to innovate bespoke offerings that leverage Deloitte’s cross-service skill sets and capabilities to address the individual needs of biotechs at different stages of their development cycle.


Click to enlarge image

To ensure successful build and scale-up of the enterprise, defining the capability requirements for successful launch is key. We support biotech and medtech companies in understanding what maturity level is optimal, which capabilities need to be fully operational and by when, how to overcome key challenges in acquiring specific capabilities and which to build in-house vs. outsource, all based on their launch strategies, priorities and goals. We would like to partner with biotech and medtech companies and de-risk the scaling-up journey. The level of Deloitte’s involvement as a strategic partner can take a variety of forms, ranging from Deloitte being on-site and leading the execution to full autonomy for the partners, with Deloitte providing assistance as and when necessary as a strategic advisor.


How to ‘ACE’ geographical expansion in Europe

Deloitte Propel

Cloud Accounting Services to support ambitious and fast-growth start-ups and SMEs

Realising a biotech’s potential

What is required to scale successfully?

Biotech’s presence in overall biopharma research and development has been increasing in recent years with a leading role in developing COVID-19 vaccines or treatments today.

Key contacts

Hanno Ronte

Hanno Ronte


Hanno is a partner at Monitor Deloitte, our strategy consultancy business. He has more than 20 years of consulting experience primarily in the healthcare and life sciences sector. Hanno leads the Life... More